joshua0111
2021-07-22
Nice
Here's Why Cassava Sciences Is Surging Today<blockquote>这就是木薯科学如今蓬勃发展的原因</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
2
8
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":172978116,"tweetId":"172978116","gmtCreate":1626931292135,"gmtModify":1633769604902,"author":{"id":3579878222573636,"idStr":"3579878222573636","authorId":3579878222573636,"authorIdStr":"3579878222573636","name":"joshua0111","avatar":"https://static.tigerbbs.com/662a143659b3954c78c2e0a2c91c466b","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":7,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body><p>Nice</p></body></html>","htmlText":"<html><head></head><body><p>Nice</p></body></html>","text":"Nice","highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/172978116","repostId":1146624774,"repostType":4,"repost":{"id":"1146624774","kind":"news","pubTimestamp":1626926115,"share":"https://www.laohu8.com/m/news/1146624774?lang=zh_CN&edition=full","pubTime":"2021-07-22 11:55","market":"us","language":"en","title":"Here's Why Cassava Sciences Is Surging Today<blockquote>这就是木薯科学如今蓬勃发展的原因</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1146624774","media":"The Motley Fool","summary":"Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzhei","content":"<p><b>Key Points</b></p><p><blockquote><b>要点</b></blockquote></p><p> <ul> <li>Cassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in an open-label study.</li> </ul> <h2><b>What happened</b></h2> Shares of <b><a href=\"https://laohu8.com/S/SAVA\">Cassava Sciences Inc</a></b>, a clinical-stage biopharmaceutical company, gained 26.6% as of 3:05 p.m. EDT on Wednesday. Investors are anticipating a new set of clinical-trial data from the company's lead candidate, simufilam, to be presented at the Alzheimer's Association International Conference (AAIC) later this month.</p><p><blockquote><ul><li>Cassava Sciences 将在一项开放标签研究中公布首批 50 名阿尔茨海默病患者的中期分析结果，这些患者完成了其主要候选药物 simufilam 的九个月治疗。</li></ul><h2><b>发生了什么事</b></h2>股份<b><a href=\"https://laohu8.com/S/SAVA\">木薯科学公司</a></b>截至下午 3:05，一家临床阶段生物制药公司上涨 26.6%。美国东部时间周三。投资者预计该公司主要候选药物 simufilam 的一组新的临床试验数据将于本月晚些时候在阿尔茨海默氏症协会国际会议 (AAIC) 上公布。</blockquote></p><p> <h2><b>So what</b></h2> The FDA's controversial approval of Aduhelm from <b><a href=\"https://laohu8.com/S/BIIB\">Biogen</a></b> this June has many retail investors excited about the next potential Alzheimer's disease treatment. More than 6 million Americans are living with this progressive and ultimately fatal form of dementia, and the only available treatmentisn't supported by evidence of efficacy.</p><p><blockquote><h2><b>那又怎样</b></h2>FDA 对 Aduhelm 的争议性批准<b><a href=\"https://laohu8.com/S/BIIB\">百健</a></b>今年六月，许多散户投资者对下一个潜在的阿尔茨海默病治疗方法感到兴奋。超过600万美国人患有这种进行性并最终致命的痴呆症，而唯一可用的治疗方法没有疗效证据支持。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/283ff788d77e7317a9f096803e24ca4f\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\">IMAGE SOURCE: GETTY IMAGES.</p><p><blockquote>图片来源：盖蒂图片社。</blockquote></p><p> Cassava Sciences stock jumped higher on Wednesday because the company simply announced an upcoming presentation at AAIC's annual conference. On July 29, 2021, the company will present new data from a phase 2 trial with simufilam, a potential first-in-class stabilizer of a structural protein called filamin A.</p><p><blockquote>Cassava Sciences 股价周三上涨，因为该公司只是宣布即将在 AAIC 年会上进行演讲。2021年7月29日，该公司将展示simufilam的2期试验的新数据，simufilam是一种名为filamin A的结构蛋白的潜在一流稳定剂。</blockquote></p><p> <h2><b>Now what</b></h2> Signs that simufilam can help slow down patients' loss of cognitive abilities have beenencouragingand worthy of further study. At recent prices, though, Cassava Sciences sports a $4.6 billion market cap. That's a lot for a company with no products to sell and oneexperimental drugin mid-stage testing.</p><p><blockquote><h2><b>现在呢</b></h2>simufilam可以帮助减缓患者认知能力丧失的迹象令人鼓舞，值得进一步研究。不过，按最近的价格计算，Cassava Sciences 的市值为 46 亿美元。对于一家没有产品销售且正在进行中期测试的实验性药物的公司来说，这是一个很大的数字。</blockquote></p><p> Last September, Cassava Sciences showed how 28 days of treatment with simufilam significantly reduced signs of worsening dementia as measured from samples of cerebrospinal fluid (CSF). Cognitive measurements from this phase 2 study showed signs of a benefit compared to a placebo, but the company hasn't even started a phase 3 trial that could support a new drug application.</p><p><blockquote>去年 9 月，Cassava Sciences 展示了 28 天的 simufilam 治疗如何显着减少从脑脊液 (CSF) 样本中测量的痴呆症恶化迹象。这项 2 期研究的认知测量显示出与安慰剂相比有益的迹象，但该公司甚至尚未开始可以支持新药申请的 3 期试验。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Cassava Sciences Is Surging Today<blockquote>这就是木薯科学如今蓬勃发展的原因</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Cassava Sciences Is Surging Today<blockquote>这就是木薯科学如今蓬勃发展的原因</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">The Motley Fool</strong><span class=\"h-time small\">2021-07-22 11:55</span>\n</p>\n</h4>\n</header>\n<article>\n<p><b>Key Points</b></p><p><blockquote><b>要点</b></blockquote></p><p> <ul> <li>Cassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in an open-label study.</li> </ul> <h2><b>What happened</b></h2> Shares of <b><a href=\"https://laohu8.com/S/SAVA\">Cassava Sciences Inc</a></b>, a clinical-stage biopharmaceutical company, gained 26.6% as of 3:05 p.m. EDT on Wednesday. Investors are anticipating a new set of clinical-trial data from the company's lead candidate, simufilam, to be presented at the Alzheimer's Association International Conference (AAIC) later this month.</p><p><blockquote><ul><li>Cassava Sciences 将在一项开放标签研究中公布首批 50 名阿尔茨海默病患者的中期分析结果，这些患者完成了其主要候选药物 simufilam 的九个月治疗。</li></ul><h2><b>发生了什么事</b></h2>股份<b><a href=\"https://laohu8.com/S/SAVA\">木薯科学公司</a></b>截至下午 3:05，一家临床阶段生物制药公司上涨 26.6%。美国东部时间周三。投资者预计该公司主要候选药物 simufilam 的一组新的临床试验数据将于本月晚些时候在阿尔茨海默氏症协会国际会议 (AAIC) 上公布。</blockquote></p><p> <h2><b>So what</b></h2> The FDA's controversial approval of Aduhelm from <b><a href=\"https://laohu8.com/S/BIIB\">Biogen</a></b> this June has many retail investors excited about the next potential Alzheimer's disease treatment. More than 6 million Americans are living with this progressive and ultimately fatal form of dementia, and the only available treatmentisn't supported by evidence of efficacy.</p><p><blockquote><h2><b>那又怎样</b></h2>FDA 对 Aduhelm 的争议性批准<b><a href=\"https://laohu8.com/S/BIIB\">百健</a></b>今年六月，许多散户投资者对下一个潜在的阿尔茨海默病治疗方法感到兴奋。超过600万美国人患有这种进行性并最终致命的痴呆症，而唯一可用的治疗方法没有疗效证据支持。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/283ff788d77e7317a9f096803e24ca4f\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\">IMAGE SOURCE: GETTY IMAGES.</p><p><blockquote>图片来源：盖蒂图片社。</blockquote></p><p> Cassava Sciences stock jumped higher on Wednesday because the company simply announced an upcoming presentation at AAIC's annual conference. On July 29, 2021, the company will present new data from a phase 2 trial with simufilam, a potential first-in-class stabilizer of a structural protein called filamin A.</p><p><blockquote>Cassava Sciences 股价周三上涨，因为该公司只是宣布即将在 AAIC 年会上进行演讲。2021年7月29日，该公司将展示simufilam的2期试验的新数据，simufilam是一种名为filamin A的结构蛋白的潜在一流稳定剂。</blockquote></p><p> <h2><b>Now what</b></h2> Signs that simufilam can help slow down patients' loss of cognitive abilities have beenencouragingand worthy of further study. At recent prices, though, Cassava Sciences sports a $4.6 billion market cap. That's a lot for a company with no products to sell and oneexperimental drugin mid-stage testing.</p><p><blockquote><h2><b>现在呢</b></h2>simufilam可以帮助减缓患者认知能力丧失的迹象令人鼓舞，值得进一步研究。不过，按最近的价格计算，Cassava Sciences 的市值为 46 亿美元。对于一家没有产品销售且正在进行中期测试的实验性药物的公司来说，这是一个很大的数字。</blockquote></p><p> Last September, Cassava Sciences showed how 28 days of treatment with simufilam significantly reduced signs of worsening dementia as measured from samples of cerebrospinal fluid (CSF). Cognitive measurements from this phase 2 study showed signs of a benefit compared to a placebo, but the company hasn't even started a phase 3 trial that could support a new drug application.</p><p><blockquote>去年 9 月，Cassava Sciences 展示了 28 天的 simufilam 治疗如何显着减少从脑脊液 (CSF) 样本中测量的痴呆症恶化迹象。这项 2 期研究的认知测量显示出与安慰剂相比有益的迹象，但该公司甚至尚未开始可以支持新药申请的 3 期试验。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/\">The Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://www.fool.com/investing/2021/07/21/heres-why-cassava-sciences-is-surging-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1146624774","content_text":"Key Points\n\nCassava Sciences will present the results of an interim analysis for the first 50 Alzheimer's disease patients to complete nine months of treatment with its lead candidate, simufilam, in an open-label study.\n\nWhat happened\nShares of Cassava Sciences Inc, a clinical-stage biopharmaceutical company, gained 26.6% as of 3:05 p.m. EDT on Wednesday. Investors are anticipating a new set of clinical-trial data from the company's lead candidate, simufilam, to be presented at the Alzheimer's Association International Conference (AAIC) later this month.\nSo what\nThe FDA's controversial approval of Aduhelm from Biogen this June has many retail investors excited about the next potential Alzheimer's disease treatment. More than 6 million Americans are living with this progressive and ultimately fatal form of dementia, and the only available treatmentisn't supported by evidence of efficacy.\nIMAGE SOURCE: GETTY IMAGES.\nCassava Sciences stock jumped higher on Wednesday because the company simply announced an upcoming presentation at AAIC's annual conference. On July 29, 2021, the company will present new data from a phase 2 trial with simufilam, a potential first-in-class stabilizer of a structural protein called filamin A.\nNow what\nSigns that simufilam can help slow down patients' loss of cognitive abilities have beenencouragingand worthy of further study. At recent prices, though, Cassava Sciences sports a $4.6 billion market cap. That's a lot for a company with no products to sell and oneexperimental drugin mid-stage testing.\nLast September, Cassava Sciences showed how 28 days of treatment with simufilam significantly reduced signs of worsening dementia as measured from samples of cerebrospinal fluid (CSF). Cognitive measurements from this phase 2 study showed signs of a benefit compared to a placebo, but the company hasn't even started a phase 3 trial that could support a new drug application.","news_type":1,"symbols_score_info":{"SAVA":0.9,"BIIB":0.9}},"isVote":1,"tweetType":1,"viewCount":693,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/172978116"}
精彩评论